Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Mycotoxins in the gastrointestinal lumen are toxic secondary metabolites produced by fungi such as Aspergillus, Fusarium, and Penicillium that contaminate food supplies worldwide [WHO, 2018]. Upon ingestion, these toxins interact with the intestinal mucosa, where they can disrupt tight junction proteins, induce oxidative stress, and trigger pro-inflammatory cytokine release, leading to impaired gut barrier function [Ghareeb et al., 2015, Toxins]. Major classes include aflatoxins, which are potent hepatocarcinogens, and trichothecenes like deoxynivalenol, which cause acute gastrointestinal distress [NIH, 2023]. Therapeutic strategies target these toxins within the GI lumen to prevent their systemic absorption and subsequent organ toxicity. This is primarily achieved through the use of adsorbents like activated charcoal or clay minerals that sequester the toxins, or through specific enzymes that biotransform them into non-toxic metabolites [EFSA, 2017].
Physical adsorption and sequestration to prevent systemic absorption; enzymatic degradation into non-toxic metabolites.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Mycotoxins in gastrointestinal lumen.